Literature DB >> 27004003

Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors.

Noriko Ihana-Sugiyama1, Naoyoshi Nagata1, Ritsuko Yamamoto-Honda1, Eiko Izawa1, Hiroshi Kajio1, Takuro Shimbo1, Masafumi Kakei1, Naomi Uemura1, Junichi Akiyama1, Mitsuhiko Noda1.   

Abstract

AIM: To determine the bowel symptoms associated with diabetes and diabetes-related factors after excluding gastrointestinal (GI) organic diseases.
METHODS: Participants were 4738 (603 diabetic and 4135 non-diabetic) patients who underwent colonoscopy and completed a questionnaire. On the day of pre-colonoscopy, 9 symptoms (borborygmus, abdominal distension, increased flatus, constipation, diarrhea, loose stools, hard stools, fecal urgency, and incomplete evacuation) were prospectively evaluated on a 7-point Likert scale. The test-retest reliability of the bowel symptom scores from the baseline and second questionnaires was analyzed using kappa statistics. Associations between bowel symptom scores and diabetes or diabetes-related factors were analyzed by a rank-ordered logistic model adjusted for related confounders, and odds ratios (ORs) were estimated.
RESULTS: In multivariate analysis, constipation [adjusted odds ratio (AOR) = 1.57, CI: 1.33-1.85, P < 0.01] and hard stools (AOR = 1.56, CI: 1.33-1.84, P < 0.01) were associated with diabetes, and fecal urgency (AOR = 1.16, CI: 0.99-1.37, P = 0.07) and incomplete evacuation (AOR = 1.16, CI: 1.00-1.36, P = 0.06) were marginally associated with diabetes. These symptoms remained associated even after excluding organic GI diseases on colonoscopy. Test-retest reliability of symptom score with a mean duration of 3.2 mo was good (mean kappa, 0.69). Associations of symptoms with diabetes-related factors were found; constipation with HbA1c ≥ 8.0% (AOR = 2.11, CI: 1.19-3.73), body mass index (BMI) < 25 (AOR = 2.11, CI: 1.22-3.66), and insulin use (AOR = 1.90, CI: 1.08-3.36); hard stools with diabetes duration (AOR = 1.03, CI: 1.00-1.07); fecal urgency with BMI < 25 (AOR = 1.73, CI: 1.00-2.98); and incomplete evacuation with BMI < 25 (AOR = 2.60, CI: 1.52-4.43), serum creatinine level (AOR = 1.27, CI: 1.10-1.47), and insulin use (AOR = 1.92, CI: 1.09-3.38).
CONCLUSION: Diabetes is associated with constipation, hard stools, fecal urgency, and incomplete evacuation, and poor glycemic control, duration, leanness, and nephropathy affect the risk of these symptoms.

Entities:  

Keywords:  Decreased passage of stools; Diabetic complications; Functional bowel disease; Gastrointestinal symptom rating scale

Mesh:

Year:  2016        PMID: 27004003      PMCID: PMC4790001          DOI: 10.3748/wjg.v22.i11.3252

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  Diabetic autonomic neuropathy.

Authors:  Aaron I Vinik; Raelene E Maser; Braxton D Mitchell; Roy Freeman
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

2.  Gastrointestinal tract symptoms among persons with diabetes mellitus in the community.

Authors:  D Maleki; G R Locke; M Camilleri; A R Zinsmeister; B P Yawn; C Leibson; L J Melton
Journal:  Arch Intern Med       Date:  2000-10-09

3.  Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests.

Authors:  Su Youn Nam; Byung Chang Kim; Kum Hei Ryu; Bum Joon Park
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

Review 4.  The kappa statistic in reliability studies: use, interpretation, and sample size requirements.

Authors:  Julius Sim; Chris C Wright
Journal:  Phys Ther       Date:  2005-03

5.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

6.  Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus.

Authors:  P Bytzer; N J Talley; M P Jones; M Horowitz
Journal:  Aliment Pharmacol Ther       Date:  2001-01       Impact factor: 8.171

7.  GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications.

Authors:  Peter Bytzer; Nicholas J Talley; Johann Hammer; Lisa J Young; Michael P Jones; Michael Horowitz
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

Review 8.  Disorders of gastrointestinal motility associated with diabetes mellitus.

Authors:  M Feldman; L R Schiller
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  Effects of demographic factors, body mass index, alcohol drinking and smoking habits on irritable bowel syndrome: a case control study.

Authors:  N Farzaneh; M Ghobaklou; B Moghimi-Dehkordi; N Naderi; F Fadai
Journal:  Ann Med Health Sci Res       Date:  2013-07
View more
  9 in total

1.  Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats.

Authors:  Yun Wang; Xinyu Xu; Lin Lin
Journal:  Int J Mol Med       Date:  2022-05-11       Impact factor: 5.314

2.  Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey.

Authors:  Vikram Rangan; Shuji Mitsuhashi; Prashant Singh; Sarah Ballou; William Hirsch; Thomas Sommers; Judy Nee; Johanna Iturrino; Anthony Lembo
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 11.382

Review 3.  Diabetes-induced mechanophysiological changes in the small intestine and colon.

Authors:  Mirabella Zhao; Donghua Liao; Jingbo Zhao
Journal:  World J Diabetes       Date:  2017-06-15

4.  Prevalence and Risk Factors for Opioid-Induced Constipation in an Older National Veteran Cohort.

Authors:  Fern FitzHenry; Svetlana K Eden; Jason Denton; Hui Cao; Aize Cao; Ruth Reeves; Guanhua Chen; Glenn Gobbel; Nancy Wells; Michael E Matheny
Journal:  Pain Res Manag       Date:  2020-03-29       Impact factor: 3.037

5.  The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients.

Authors:  Małgorzata Reszczyńska; Radosław Kempiński
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

6.  Association Between Psychological Distress and Stress-Related Symptoms and Increased Risk of Type 2 Diabetes in Male Individuals: An Observational Study.

Authors:  Kaoru Takahashi; Tsutomu Kamino; Toshinari Yasuda; Akiko Suganuma; Naoki Sakane
Journal:  J Clin Med Res       Date:  2020-12-18

7.  Constipation Is a Frequent Problem Associated with Vascular Complications in Patients with Type 2 Diabetes: A Cross-sectional Study.

Authors:  Hiroyuki Ito; Kiyoko Ito; Mahika Tanaka; Mayumi Hokamura; Mari Tanaka; Eiji Kusano; Jiro Kondo; Takuma Izutsu; Suzuko Matsumoto; Hideyuki Inoue; Shinichi Antoku; Tomoko Yamasaki; Toshiko Mori; Michiko Togane
Journal:  Intern Med       Date:  2022-05-01       Impact factor: 1.282

8.  Severe grade of melanosis coli is associated with a higher detection rate of colorectal adenoma.

Authors:  Ryo Katsumata; Noriaki Manabe; Yasumasa Monobe; Tomohiro Tanikawa; Maki Ayaki; Mitsuhiko Suehiro; Minoru Fujita; Tomoari Kamada; Ken Haruma; Hirofumi Kawamoto
Journal:  J Clin Biochem Nutr       Date:  2022-08-10       Impact factor: 3.179

9.  Constipation and diabetic kidney disease: The Fukuoka Diabetes Registry.

Authors:  Toshiaki Ohkuma; Masanori Iwase; Hiroki Fujii; Hitoshi Ide; Yuji Komorita; Masahito Yoshinari; Yutaro Oku; Taiki Higashi; Ayaka Oshiro; Udai Nakamura; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2021-06-26       Impact factor: 2.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.